Theravance Biopharma Inc (0TB) — Cash Flow-to-Debt Ratio
Theravance Biopharma Inc (0TB) has a Cash Flow-to-Debt Ratio of -0.04x as of September 2025, meaning its operating cash flow of €-6.51 Million could theoretically repay 0% of its total liabilities (€182.78 Million) in one year. See Theravance Biopharma Inc free cash flow efficiency to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Theravance Biopharma Inc Cash Flow-to-Debt Ratio (2014–2024)
Historical debt coverage capacity for Theravance Biopharma Inc across 11 annual periods. Also explore 0TB net asset momentum to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Theravance Biopharma Inc (2014–2024)
Year-by-year debt coverage analysis for Theravance Biopharma Inc. For market capitalisation and broader financial context, see Theravance Biopharma Inc (0TB) market capitalisation.
| Year | CF-to-Debt Ratio | Operating CF (EUR) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -0.06x | €-11.54 Million | €178.62 Million | ▲ +59.6% |
| 2023 | -0.16x | €-27.00 Million | €169.00 Million | ▲ +85.9% |
| 2022 | -1.13x | €-186.99 Million | €165.60 Million | ▼ -287.5% |
| 2021 | -0.29x | €-207.86 Million | €713.39 Million | ▲ +10.1% |
| 2020 | -0.32x | €-250.40 Million | €772.81 Million | ▲ +13.9% |
| 2019 | -0.38x | €-238.20 Million | €632.67 Million | ▼ -104.1% |
| 2018 | -0.18x | €-112.87 Million | €611.82 Million | ▲ +70.1% |
| 2017 | -0.62x | €-201.05 Million | €326.22 Million | ▼ -79.9% |
| 2016 | -0.34x | €-98.99 Million | €289.02 Million | ▲ +88.4% |
| 2015 | -2.96x | €-168.86 Million | €57.05 Million | ▲ +18.9% |
| 2014 | -3.65x | €-175.16 Million | €47.98 Million | — |